Ackr3, also known as CXCR7, is an atypical chemokine receptor belonging to the class A G protein-coupled receptor family. It plays crucial roles in various biological processes, such as being involved in the CXCL12-CXCR4 axis. This axis is associated with multiple signaling pathways like the STAT3 pathway, which is significant in the progression of various diseases and neoplasms [1]. Ackr3 also has implications in processes related to platelet pathophysiology, skin homeostasis, and acts as a drug target in diseases like HIV infection, cancer, and inflammation [2,3,4].

In cancer, studies have shown that Ackr3 is overexpressed in numerous cancer types including breast, lung, brain, and renal cell carcinoma. In renal cell carcinoma, it orchestrates Hedgehog-GLI1 signaling to promote cancer progression. In lymphoma, Ackr3 promotes CXCL12/CXCR4-mediated cell-to-cell-induced lymphoma migration through LTB4 production [5,6,8]. In cardiovascular diseases, it exerts atheroprotective, cardioprotective, and anti-thrombotic effects [7].

In conclusion, Ackr3 is a key player in multiple biological processes and disease conditions. Its overexpression in various cancers and its role in cardiovascular diseases highlight its significance. The study of Ackr3 using genetic models like KO/CKO mouse models could potentially unveil more about its function and lead to the development of targeted therapies for these diseases.